Company: ANIX
Filing Date: 2025-03-11
Form Type: 10-Q
Source: 0001493152-25-009854
Chunk: 17

Company: Anixa Biosciences Inc
Filing Date: 2025-03-11
Form: 10-Q
Item: Part I, Item 8
Chunk 17
---
under certain technology license agreements related to our therapeutic and vaccine development programs for the next twelve months, were
approximately $150,000.

Research & Development Agreements

We have entered into certain research
and development agreements with various collaboration partners and third-party vendors related to i) the manufacturing of materials necessary
for the expected Phase 2 clinical trial of our breast cancer vaccine, ii) the discovery of new vaccine targets in high incidence malignancies
in prostate, lung and colon and iii) the further development of our CAR-T technology. As of January 31, 2025, future payments the Company
may make under these agreements, dependent upon, among other things, development of analytical methods, formulation feasibility studies,
stability testing and results of manufacturing processes, may be approximately $3.7 million and such payments may be made over up to a
five-year period.

11. SEGMENT INFORMATION

We follow the accounting guidance
of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management
approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments
within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed
on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating
characteristics: (i) Cancer Vaccines, (ii) CAR-T Therapeutics, and (iii) Other. The following represents selected financial information
for our segments for the three months ended January 31, 2025 and 2024 and as of January 31, 2025 and October 31, 2024 (in thousands):

 SCHEDULE OF SEGMENT INFORMATION 

    2025  
    2024 

    For the Three Months Ended  January 31, 

    2025  
    2024 
  
    Net loss: 

    Cancer Vaccines 
    $(2,018) 
    $(1,756)
  
    CAR-T Therapeutics 
     (1,177) 
     (1,525)
  
    Other 
     (18) 
     (9)
  
    Total 
    $(3,213) 
    $(3,290)
  
    Net income (loss) 
    $(3,213) 
    $(3,290)

    Total operating costs and